Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPT challenge and 4-week AMPT trial in adults with velocardiofacial syndrome and severe intellectual impairment
NL-OMON31666Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of metyrosine in Velocardiofacial syndrome (VCFS), intellectual disability (ID), No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity and 2 more (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Plasma dopamine metabolite and related biochemical measures, Urine catecholamine metabolite measures and 2 more. Planned start Jul 2008; status: withdrawn.
02
Drugs
metyrosine
03
Conditions
Velocardiofacial syndrome (VCFS)intellectual disability (ID)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.DementiaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON31666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31666.